Eric Peterson
Concepts (279)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Methamphetamine | 16 | 2020 | 233 | 4.330 |
Why?
| Single-Chain Antibodies | 6 | 2020 | 28 | 2.600 |
Why?
| Amphetamine-Related Disorders | 5 | 2020 | 125 | 1.980 |
Why?
| Radial Artery | 5 | 2020 | 38 | 1.890 |
Why?
| Antibodies, Monoclonal | 10 | 2014 | 562 | 1.480 |
Why?
| Immunoglobulin Fragments | 3 | 2013 | 19 | 1.230 |
Why?
| Cerebral Angiography | 7 | 2020 | 106 | 1.150 |
Why?
| Endovascular Procedures | 8 | 2020 | 186 | 1.140 |
Why?
| Central Nervous System Stimulants | 2 | 2020 | 255 | 1.060 |
Why?
| Haptens | 4 | 2014 | 14 | 1.020 |
Why?
| Intracranial Aneurysm | 3 | 2020 | 54 | 0.990 |
Why?
| Embolization, Therapeutic | 4 | 2019 | 98 | 0.870 |
Why?
| Nanoparticles | 2 | 2015 | 173 | 0.840 |
Why?
| Immunoglobulin Fc Fragments | 2 | 2020 | 12 | 0.800 |
Why?
| Dependovirus | 2 | 2020 | 102 | 0.790 |
Why?
| Artificial Gene Fusion | 1 | 2020 | 13 | 0.750 |
Why?
| Immunoglobulin Variable Region | 4 | 2020 | 33 | 0.710 |
Why?
| Genetic Therapy | 1 | 2020 | 121 | 0.690 |
Why?
| Polyethylene Glycols | 2 | 2016 | 106 | 0.680 |
Why?
| Cerebrovascular Disorders | 1 | 2019 | 53 | 0.670 |
Why?
| Drug Design | 3 | 2019 | 133 | 0.650 |
Why?
| Genetic Vectors | 1 | 2018 | 139 | 0.630 |
Why?
| Nanomedicine | 1 | 2016 | 22 | 0.560 |
Why?
| Hemangiopericytoma | 1 | 2015 | 1 | 0.550 |
Why?
| Epitopes | 2 | 2014 | 89 | 0.520 |
Why?
| Stroke | 5 | 2022 | 524 | 0.520 |
Why?
| Mice, Inbred BALB C | 6 | 2020 | 368 | 0.510 |
Why?
| Radiometry | 1 | 2014 | 124 | 0.480 |
Why?
| Prospective Studies | 10 | 2022 | 2604 | 0.470 |
Why?
| Substance-Related Disorders | 4 | 2019 | 671 | 0.460 |
Why?
| Animals | 18 | 2021 | 14385 | 0.440 |
Why?
| Male | 22 | 2021 | 27312 | 0.430 |
Why?
| Brain Neoplasms | 1 | 2015 | 284 | 0.420 |
Why?
| Ophthalmic Artery | 1 | 2011 | 3 | 0.400 |
Why?
| Retinal Neoplasms | 1 | 2011 | 13 | 0.400 |
Why?
| Retinoblastoma | 1 | 2011 | 16 | 0.400 |
Why?
| Young Adult | 10 | 2022 | 4308 | 0.370 |
Why?
| Melphalan | 1 | 2011 | 180 | 0.370 |
Why?
| Treatment Outcome | 11 | 2022 | 5604 | 0.360 |
Why?
| Retrospective Studies | 10 | 2022 | 6432 | 0.330 |
Why?
| Rats, Sprague-Dawley | 5 | 2019 | 1663 | 0.310 |
Why?
| Brain Ischemia | 3 | 2018 | 169 | 0.310 |
Why?
| Aged | 12 | 2022 | 10041 | 0.310 |
Why?
| Aged, 80 and over | 7 | 2020 | 3429 | 0.310 |
Why?
| Middle Aged | 13 | 2022 | 13070 | 0.300 |
Why?
| Neurosurgical Procedures | 3 | 2020 | 120 | 0.300 |
Why?
| Immunotherapy | 1 | 2009 | 263 | 0.290 |
Why?
| Adult | 13 | 2022 | 14182 | 0.290 |
Why?
| Mice | 8 | 2021 | 6413 | 0.280 |
Why?
| Half-Life | 2 | 2016 | 92 | 0.280 |
Why?
| Polyvinyls | 3 | 2015 | 15 | 0.280 |
Why?
| Stents | 3 | 2020 | 375 | 0.280 |
Why?
| Tissue Distribution | 2 | 2016 | 178 | 0.270 |
Why?
| Models, Molecular | 6 | 2017 | 423 | 0.270 |
Why?
| Female | 19 | 2022 | 28418 | 0.270 |
Why?
| Amino Acid Sequence | 6 | 2017 | 767 | 0.270 |
Why?
| Vaccines | 2 | 2019 | 65 | 0.260 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2014 | 79 | 0.260 |
Why?
| Humans | 24 | 2022 | 54246 | 0.260 |
Why?
| Adolescent | 8 | 2022 | 6885 | 0.250 |
Why?
| Antibodies, Viral | 3 | 2020 | 124 | 0.240 |
Why?
| Sulfhydryl Compounds | 2 | 2014 | 19 | 0.230 |
Why?
| Molecular Sequence Data | 5 | 2014 | 980 | 0.230 |
Why?
| Cricetinae | 3 | 2020 | 209 | 0.230 |
Why?
| Antineoplastic Agents | 1 | 2011 | 1300 | 0.210 |
Why?
| Sclerotherapy | 1 | 2022 | 47 | 0.210 |
Why?
| Antibodies, Neutralizing | 2 | 2020 | 75 | 0.200 |
Why?
| Protein Binding | 5 | 2017 | 736 | 0.200 |
Why?
| Protein Processing, Post-Translational | 2 | 2021 | 183 | 0.200 |
Why?
| Peptide Library | 1 | 2020 | 29 | 0.190 |
Why?
| Immunoglobulin Heavy Chains | 1 | 2020 | 54 | 0.190 |
Why?
| Analgesics, Non-Narcotic | 1 | 2021 | 140 | 0.180 |
Why?
| Vascular Malformations | 1 | 2022 | 101 | 0.180 |
Why?
| Benchmarking | 1 | 2020 | 73 | 0.180 |
Why?
| Catheterization, Peripheral | 1 | 2020 | 63 | 0.180 |
Why?
| Locomotion | 1 | 2020 | 83 | 0.180 |
Why?
| Carotid Artery Diseases | 2 | 2019 | 38 | 0.170 |
Why?
| Tantalum | 2 | 2015 | 5 | 0.170 |
Why?
| Liver Cirrhosis | 1 | 2021 | 216 | 0.170 |
Why?
| Rats | 4 | 2019 | 3415 | 0.170 |
Why?
| Antibody Affinity | 2 | 2020 | 11 | 0.170 |
Why?
| Femoral Artery | 1 | 2020 | 122 | 0.170 |
Why?
| Benzodioxoles | 1 | 2019 | 56 | 0.170 |
Why?
| Drug Combinations | 2 | 2015 | 128 | 0.170 |
Why?
| Histones | 1 | 2021 | 335 | 0.170 |
Why?
| Intraoperative Complications | 1 | 2020 | 125 | 0.170 |
Why?
| Pyrrolidines | 1 | 2019 | 88 | 0.160 |
Why?
| Recombinant Proteins | 3 | 2017 | 569 | 0.160 |
Why?
| Aneurysm, False | 1 | 2019 | 49 | 0.160 |
Why?
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2017 | 3 | 0.160 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2017 | 9 | 0.160 |
Why?
| Thrombectomy | 1 | 2018 | 68 | 0.160 |
Why?
| Acetaminophen | 1 | 2021 | 349 | 0.160 |
Why?
| Arteries | 1 | 2018 | 101 | 0.160 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2017 | 30 | 0.160 |
Why?
| Forecasting | 2 | 2020 | 161 | 0.160 |
Why?
| Cerebrovascular Circulation | 1 | 2019 | 137 | 0.160 |
Why?
| Vaccines, Conjugate | 2 | 2014 | 10 | 0.160 |
Why?
| Maleimides | 2 | 2014 | 9 | 0.160 |
Why?
| Serum Albumin, Bovine | 2 | 2014 | 25 | 0.160 |
Why?
| Crystallography, X-Ray | 2 | 2017 | 178 | 0.150 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 85 | 0.150 |
Why?
| Pneumonia, Viral | 1 | 2020 | 184 | 0.150 |
Why?
| Coronavirus Infections | 1 | 2020 | 192 | 0.150 |
Why?
| Carotid Artery, External | 1 | 2015 | 3 | 0.140 |
Why?
| Polyvinyl Alcohol | 1 | 2015 | 7 | 0.140 |
Why?
| Central Nervous System Vascular Malformations | 1 | 2015 | 13 | 0.140 |
Why?
| Dendrimers | 1 | 2015 | 1 | 0.140 |
Why?
| Antigen-Antibody Reactions | 1 | 2015 | 18 | 0.140 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 240 | 0.140 |
Why?
| Hemolysis | 1 | 2015 | 32 | 0.130 |
Why?
| Molecular Structure | 2 | 2013 | 319 | 0.130 |
Why?
| Cricetulus | 1 | 2015 | 102 | 0.130 |
Why?
| CHO Cells | 1 | 2015 | 123 | 0.130 |
Why?
| Blood Loss, Surgical | 1 | 2015 | 79 | 0.130 |
Why?
| Erythrocytes | 1 | 2015 | 98 | 0.130 |
Why?
| Cystine | 1 | 2014 | 15 | 0.130 |
Why?
| Molecular Weight | 1 | 2014 | 100 | 0.130 |
Why?
| Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 124 | 0.120 |
Why?
| Drug-Eluting Stents | 1 | 2015 | 116 | 0.120 |
Why?
| Child, Preschool | 4 | 2022 | 4146 | 0.120 |
Why?
| Adenosine Monophosphate | 1 | 2013 | 15 | 0.120 |
Why?
| Nickel | 1 | 2013 | 13 | 0.120 |
Why?
| Antibody Specificity | 2 | 2017 | 48 | 0.120 |
Why?
| Amphetamine | 1 | 2014 | 42 | 0.120 |
Why?
| Tandem Mass Spectrometry | 1 | 2015 | 248 | 0.120 |
Why?
| Sulfates | 1 | 2013 | 27 | 0.120 |
Why?
| Genetic Engineering | 1 | 2014 | 27 | 0.120 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2015 | 377 | 0.120 |
Why?
| Signal Recognition Particle | 2 | 2004 | 2 | 0.120 |
Why?
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 129 | 0.120 |
Why?
| Protein Multimerization | 1 | 2013 | 54 | 0.120 |
Why?
| Protein Conformation | 1 | 2013 | 226 | 0.110 |
Why?
| Chromatography, Affinity | 1 | 2012 | 50 | 0.110 |
Why?
| Child | 5 | 2022 | 7337 | 0.100 |
Why?
| Head and Neck Neoplasms | 2 | 2015 | 335 | 0.100 |
Why?
| Vascular Neoplasms | 1 | 2011 | 20 | 0.100 |
Why?
| Proteins | 1 | 2014 | 376 | 0.100 |
Why?
| Infusions, Intra-Arterial | 1 | 2011 | 18 | 0.100 |
Why?
| Diethylhexyl Phthalate | 1 | 2011 | 4 | 0.100 |
Why?
| Ophthalmoscopy | 1 | 2011 | 19 | 0.100 |
Why?
| Eye Enucleation | 1 | 2011 | 13 | 0.100 |
Why?
| Cross Reactions | 2 | 2009 | 56 | 0.100 |
Why?
| Receptors, Steroid | 1 | 2011 | 21 | 0.100 |
Why?
| Endocrine Disruptors | 1 | 2011 | 27 | 0.100 |
Why?
| Reproducibility of Results | 1 | 2014 | 1304 | 0.100 |
Why?
| Structure-Activity Relationship | 2 | 2014 | 423 | 0.100 |
Why?
| Alternative Splicing | 1 | 2011 | 64 | 0.100 |
Why?
| Magnetic Resonance Imaging | 2 | 2015 | 1604 | 0.100 |
Why?
| Brain | 2 | 2016 | 1387 | 0.090 |
Why?
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2009 | 34 | 0.090 |
Why?
| Drug Discovery | 1 | 2009 | 90 | 0.080 |
Why?
| Dimerization | 1 | 2008 | 59 | 0.080 |
Why?
| Complementarity Determining Regions | 1 | 2007 | 2 | 0.080 |
Why?
| Drug Evaluation, Preclinical | 1 | 2008 | 158 | 0.080 |
Why?
| Chloroplasts | 2 | 2004 | 6 | 0.070 |
Why?
| Immunization, Passive | 2 | 2020 | 35 | 0.070 |
Why?
| Infant | 2 | 2015 | 3817 | 0.070 |
Why?
| Arabidopsis | 2 | 2004 | 33 | 0.070 |
Why?
| Cattle | 2 | 2020 | 224 | 0.070 |
Why?
| Binding Sites | 2 | 2017 | 440 | 0.060 |
Why?
| GTP Phosphohydrolases | 1 | 2004 | 35 | 0.060 |
Why?
| Photosynthetic Reaction Center Complex Proteins | 1 | 2002 | 2 | 0.060 |
Why?
| Interleukin-5 | 1 | 2022 | 6 | 0.050 |
Why?
| Interleukin-16 | 1 | 2022 | 2 | 0.050 |
Why?
| Vascular Endothelial Growth Factor C | 1 | 2022 | 3 | 0.050 |
Why?
| Lymphotoxin-alpha | 1 | 2022 | 10 | 0.050 |
Why?
| Interleukin-13 | 1 | 2022 | 16 | 0.050 |
Why?
| Angiogenesis Inducing Agents | 1 | 2022 | 8 | 0.050 |
Why?
| Vascular Endothelial Growth Factor D | 1 | 2022 | 8 | 0.050 |
Why?
| Interleukin-15 | 1 | 2022 | 19 | 0.050 |
Why?
| Cloning, Molecular | 2 | 2017 | 198 | 0.050 |
Why?
| Interleukin-4 | 1 | 2022 | 48 | 0.050 |
Why?
| Sclerosing Solutions | 1 | 2022 | 14 | 0.050 |
Why?
| Interleukin-2 | 1 | 2022 | 75 | 0.050 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 75 | 0.050 |
Why?
| Interleukin-12 | 1 | 2022 | 37 | 0.050 |
Why?
| Interleukin-17 | 1 | 2022 | 38 | 0.050 |
Why?
| Bleomycin | 1 | 2022 | 37 | 0.050 |
Why?
| Interleukin-8 | 1 | 2022 | 97 | 0.050 |
Why?
| Hydrophobic and Hydrophilic Interactions | 2 | 2014 | 42 | 0.050 |
Why?
| Glutamate Dehydrogenase | 1 | 2021 | 15 | 0.050 |
Why?
| HMGB1 Protein | 1 | 2021 | 17 | 0.050 |
Why?
| Keratin-18 | 1 | 2021 | 15 | 0.050 |
Why?
| Histone Code | 1 | 2021 | 32 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2022 | 230 | 0.050 |
Why?
| Methylation | 1 | 2021 | 130 | 0.050 |
Why?
| Adenosine Triphosphate | 1 | 2002 | 242 | 0.050 |
Why?
| Alanine Transaminase | 1 | 2021 | 151 | 0.050 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 1 | 2020 | 15 | 0.050 |
Why?
| Time Factors | 2 | 2018 | 3212 | 0.050 |
Why?
| Ovalbumin | 2 | 2011 | 17 | 0.050 |
Why?
| Vero Cells | 1 | 2020 | 44 | 0.050 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2020 | 24 | 0.050 |
Why?
| Mutation | 2 | 2020 | 1501 | 0.050 |
Why?
| Interleukin-6 | 1 | 2022 | 315 | 0.050 |
Why?
| Drug Administration Schedule | 1 | 2021 | 401 | 0.050 |
Why?
| Subclavian Artery | 1 | 2020 | 22 | 0.050 |
Why?
| Carotid Arteries | 1 | 2020 | 82 | 0.050 |
Why?
| Chromatin | 1 | 2021 | 156 | 0.050 |
Why?
| Immunoglobulin G | 1 | 2020 | 226 | 0.050 |
Why?
| Aorta, Thoracic | 1 | 2020 | 90 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2015 | 2387 | 0.040 |
Why?
| Hemorheology | 1 | 2019 | 14 | 0.040 |
Why?
| Carotid Artery, Internal | 1 | 2019 | 24 | 0.040 |
Why?
| Antibodies | 1 | 2019 | 178 | 0.040 |
Why?
| Cytokines | 1 | 2022 | 676 | 0.040 |
Why?
| Feasibility Studies | 1 | 2020 | 398 | 0.040 |
Why?
| Pilot Projects | 1 | 2021 | 808 | 0.040 |
Why?
| Neuroimaging | 1 | 2019 | 88 | 0.040 |
Why?
| Two-Hybrid System Techniques | 2 | 2011 | 26 | 0.040 |
Why?
| Orthomyxoviridae | 1 | 2017 | 6 | 0.040 |
Why?
| Bacterial Proteins | 1 | 2002 | 454 | 0.040 |
Why?
| Protein Interaction Domains and Motifs | 1 | 2017 | 26 | 0.040 |
Why?
| Motor Activity | 1 | 2019 | 247 | 0.040 |
Why?
| Equipment Design | 1 | 2019 | 318 | 0.040 |
Why?
| Protein Structure, Secondary | 1 | 2017 | 99 | 0.040 |
Why?
| Cohort Studies | 1 | 2022 | 1543 | 0.040 |
Why?
| Sequence Alignment | 1 | 2017 | 146 | 0.040 |
Why?
| Sequence Homology, Amino Acid | 1 | 2017 | 180 | 0.040 |
Why?
| Postoperative Complications | 2 | 2015 | 1033 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 1 | 2019 | 1476 | 0.030 |
Why?
| Pandemics | 1 | 2020 | 579 | 0.030 |
Why?
| Gene Expression | 1 | 2017 | 664 | 0.030 |
Why?
| Protein Engineering | 1 | 2014 | 21 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2015 | 514 | 0.030 |
Why?
| Molecular Conformation | 1 | 2014 | 73 | 0.030 |
Why?
| Thylakoids | 2 | 2004 | 2 | 0.030 |
Why?
| Hemorrhage | 1 | 2015 | 208 | 0.030 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2015 | 180 | 0.030 |
Why?
| Recurrence | 1 | 2015 | 690 | 0.030 |
Why?
| Fluoroscopy | 1 | 2011 | 45 | 0.030 |
Why?
| Spinal Puncture | 1 | 2011 | 20 | 0.030 |
Why?
| Magnetic Resonance Angiography | 1 | 2011 | 80 | 0.030 |
Why?
| Stereoisomerism | 1 | 2011 | 106 | 0.030 |
Why?
| Angiography | 1 | 2011 | 147 | 0.030 |
Why?
| Oxidoreductases, N-Demethylating | 1 | 2011 | 19 | 0.020 |
Why?
| COS Cells | 1 | 2011 | 78 | 0.020 |
Why?
| Enzyme Induction | 1 | 2011 | 80 | 0.020 |
Why?
| Anesthesia, General | 1 | 2011 | 96 | 0.020 |
Why?
| Drug Carriers | 1 | 2011 | 81 | 0.020 |
Why?
| Protein Isoforms | 1 | 2011 | 124 | 0.020 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 70 | 0.020 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2011 | 82 | 0.020 |
Why?
| Ligands | 1 | 2011 | 230 | 0.020 |
Why?
| Preoperative Care | 1 | 2011 | 184 | 0.020 |
Why?
| Cell Culture Techniques | 1 | 2011 | 112 | 0.020 |
Why?
| Data Collection | 1 | 2011 | 321 | 0.020 |
Why?
| Binding Sites, Antibody | 1 | 2009 | 26 | 0.020 |
Why?
| Transfection | 1 | 2011 | 399 | 0.020 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2009 | 34 | 0.020 |
Why?
| Substrate Specificity | 1 | 2009 | 209 | 0.020 |
Why?
| Immunization | 1 | 2009 | 95 | 0.020 |
Why?
| Hepatocytes | 1 | 2011 | 214 | 0.020 |
Why?
| Blotting, Western | 1 | 2011 | 683 | 0.020 |
Why?
| Water | 1 | 2009 | 102 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 490 | 0.020 |
Why?
| Carrier Proteins | 1 | 2009 | 359 | 0.020 |
Why?
| Cell Line | 1 | 2009 | 1153 | 0.020 |
Why?
| Chloroplast Proteins | 1 | 2004 | 1 | 0.020 |
Why?
| Photosystem II Protein Complex | 1 | 2004 | 4 | 0.020 |
Why?
| Apoproteins | 1 | 2004 | 11 | 0.020 |
Why?
| Ankyrins | 1 | 2004 | 10 | 0.020 |
Why?
| Hydrolysis | 1 | 2004 | 68 | 0.020 |
Why?
| Ribosomes | 1 | 2004 | 33 | 0.020 |
Why?
| Plant Proteins | 1 | 2004 | 72 | 0.020 |
Why?
| Biological Transport | 1 | 2004 | 195 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2004 | 289 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 2004 | 206 | 0.010 |
Why?
| Glutathione Transferase | 1 | 2004 | 178 | 0.010 |
Why?
| Endoplasmic Reticulum | 1 | 2004 | 123 | 0.010 |
Why?
| Gene Deletion | 1 | 2004 | 293 | 0.010 |
Why?
| Peptides | 1 | 2004 | 276 | 0.010 |
Why?
| Light-Harvesting Protein Complexes | 1 | 2002 | 2 | 0.010 |
Why?
| Protein Sorting Signals | 1 | 2002 | 10 | 0.010 |
Why?
| Protein Biosynthesis | 1 | 2004 | 273 | 0.010 |
Why?
| Plasmids | 1 | 2002 | 180 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 673 | 0.010 |
Why?
| Signal Transduction | 1 | 2004 | 1753 | 0.010 |
Why?
|
|
Peterson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|